These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 18374623)

  • 1. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
    Thorburn A; Behbakht K; Ford H
    Drug Resist Updat; 2008; 11(1-2):17-24. PubMed ID: 18374623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of death receptor pathways in oncology.
    de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
    Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of TRAIL receptor agonists in cancer treatment.
    Fulda S
    Eur J Clin Pharmacol; 2015 May; 71(5):525-7. PubMed ID: 25704217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onto better TRAILs for cancer treatment.
    de Miguel D; Lemke J; Anel A; Walczak H; Martinez-Lostao L
    Cell Death Differ; 2016 May; 23(5):733-47. PubMed ID: 26943322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.
    Dai X; Zhang J; Arfuso F; Chinnathambi A; Zayed ME; Alharbi SA; Kumar AP; Ahn KS; Sethi G
    Exp Biol Med (Maywood); 2015 Jun; 240(6):760-73. PubMed ID: 25854879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.
    Singh D; Tewari M; Singh S; Narayan G
    Future Oncol; 2021 Feb; 17(5):581-596. PubMed ID: 33401962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia.
    Saraei R; Soleimani M; Movassaghpour Akbari AA; Farshdousti Hagh M; Hassanzadeh A; Solali S
    Biomed Pharmacother; 2018 Nov; 107():1010-1019. PubMed ID: 30257312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting TRAIL towards the clinic.
    Mahalingam D; Oldenhuis CN; Szegezdi E; Giles FJ; de Vries EG; de Jong S; Nawrocki ST
    Curr Drug Targets; 2011 Dec; 12(14):2079-90. PubMed ID: 21777191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.
    Holoch PA; Griffith TS
    Eur J Pharmacol; 2009 Dec; 625(1-3):63-72. PubMed ID: 19836385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
    Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
    FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TRAIL to targeted therapy of breast cancer.
    Rahman M; Pumphrey JG; Lipkowitz S
    Adv Cancer Res; 2009; 103():43-73. PubMed ID: 19854352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The three Rs along the TRAIL: resistance, re-sensitization and reactive oxygen species (ROS).
    Mellier G; Pervaiz S
    Free Radic Res; 2012 Aug; 46(8):996-1003. PubMed ID: 22559302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
    Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
    Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL receptor signaling and therapeutics.
    Abdulghani J; El-Deiry WS
    Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Death receptor ligands, in particular TRAIL, to overcome drug resistance.
    de Jong S; Timmer T; Heijenbrok FJ; de Vries EG
    Cancer Metastasis Rev; 2001; 20(1-2):51-6. PubMed ID: 11831647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial dynamics of TRAIL death receptors in cancer cells.
    Twomey JD; Kim SR; Zhao L; Bozza WP; Zhang B
    Drug Resist Updat; 2015 Mar; 19():13-21. PubMed ID: 25840763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs.
    Wang F; Lin J; Xu R
    Curr Pharm Des; 2014; 20(42):6714-22. PubMed ID: 25269558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent advances for research on anti-tumor effects of TNF-related apoptosis-inducing ligand].
    Yao GH; Hou YY
    Wei Sheng Yan Jiu; 2006 Jan; 35(1):115-7. PubMed ID: 16598953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.